Hematologists Analyze Pipeline for Multiple Myeloma Therapeutics in New Report

Share Article

Combination therapies are, and will continue to be, the name of the game in the treatment of myeloma, according to a panel of global hematologists recently interviewed by MedPredict.

The population that can benefit from a new targeted therapeutic monotherapy is going to be negligible. The name of the game is, and will be, combination therapy.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Myeloma,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments in this disease area.

This new report captures the opinions of a panel of global experts who specialize in multiple myeloma. They provide insight into the practice-changing ramifications of the data presented at the recent American Society of Hematology conference.

“Multiple myeloma has been transformed into a chronic but still life threatening disease,” according to Jeffrey Berk, Ph.D., MedPredict’s president. “Initial response rates to standard of care are very high. Revlimid, Velcade and dexamethasone gives a 100% response rate, with the very good partial response rate being 75%. From a commercial standpoint, this means that the population that can benefit from a new targeted therapeutic monotherapy is going to be negligible. The name of the game is, and will be, combination therapy.”

With this as a backdrop, some of the topics the panel tackles in this report include:

  •     What are the key unmet needs in multiple myeloma?
  •     How do they differentiate carfilzomib from bortezomib? Pomalidomide from lenalidomide?
  •     How will safety, efficacy and economics of new combinations drive the choice of therapy?
  •     Where will other mechanisms fit – including IMiD, HDAC, CS-1, CD38, CD56, CD138, FGFR3, AKT, CD66b, IGF-1, IL6, RAF/MEK, antibody drug conjugates and vaccines?
  •     What is new in transplant? Use of anticoagulants? Risk stratification? Treatment of skeletal related events?

Companies discussed in this report include: Abbott, Aeterna Zentaris, Amgen, Bayer, BioTest, Bristol-Myers Squibb, Boehringer Ingelheim, Aris, Celgene, Centocor, Cephalon, Genentech, Genmab, Gentium, GlaxoSmithKline, ImmunoGen, Johnson & Johnson, Keryx, Merck, Millennium, Nereus, Novartis, Onyx, and Signal Genetics.

The full report may be purchased by contacting MedPredict.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
Visit website